Large outcome trials have already supported the use of SGLT-2 inhibitors not only to decrease major adverse cardiovascular events in patients with HF with reduced ejection fraction (40, 41), but also to prevent HF in patients at high risk based on established risk factors of diabetes (42) and chronic kidney disease (43). The gene discussed is SLC5A2; the disease is hydrops fetalis.